Last updated: 11/07/2018 18:10:49

A Study to Investigate Whether There is a Pharmacokinetic Interaction Between 141W94 and Clarithromycin Following Their Co-Administration to Healthy Male Volunteers.

GSK study ID
PROA1013
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A Study to Investigate Whether There is a Pharmacokinetic Interaction Between 141W94 and Clarithromycin Following Their Co-Administration to Healthy Male Volunteers.
Trial description: A Study to Investigate Whether There is a Pharmacokinetic Interaction Between 141W94 and Clarithromycin Following Their Co-Administration to Healthy Male Volunteers.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Brophy DF. Israel DS. Pastor A. Gillotin C. Chittick GE. Symonds WT. Lou Y. Sadler BM. Polk RE. Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers. Antimicrobial Agents & Chemotherapy. 44(4):978-84, 2000 Apr.
Polk RE, Israel DS, Pastor A, Gillotin C, Chittick GE, Symonds WT, Lou Y, Sadler BM. Effects of clarithromycin (CLR) on the pharmacokinetics of amprenavir (APV). 1998 ICAAC, September 24 - 27, 1998, San Diego, California
Polk RE, Israel DS, Pastor A, Sadler BM, Chittick GE, Symonds WT, Lou Y, Richards L. Effects of 141W94 and clarithromycin on P450 3A4 activity, as measured by the Erythromycin breath test. Infectious Disease Society of America annual meeting, San Francisco, CA, 1997: abstract 237.
Medical condition
Infection, Human Immunodeficiency Virus
Product
amprenavir
Collaborators
Not applicable
Study date(s)
March 1997 to July 1997
Type
Not applicable
Phase
1

Participation criteria

Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable

Trial location(s)

This study does not involve prospective enrollment of participants.

Study documents

Scientific result summary
Available language(s): English

If you wish to request for full study report, please contact - [email protected]

Results overview

Not applicable

Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1997-20-07

Plain language summaries

Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

Additional information about the trial

Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website